NKP-1339 (IT139; KP1339) is the first-in-class and potent ruthenium-based anticancer drug under clinical investigation for treating solid cancer with limited side effects. NKP-1339 induces G2/M cell cycle arrest, blockage of DNA synthesis, and induction of apoptosis via the mitochondrial pathway. NKP-1339 has a high tumor targeting potential, strongly binds to serum proteins such as albumin and transferrin and activates in the reductive tumor milieu.

纯度：≥98%

CAS：197723-00-5